Mer­ck­'s Keytru­da scores first win in ad­ju­vant kid­ney can­cer, giv­ing it a leg up on check­point in­hibitor ri­vals

Mer­ck is mak­ing room for yet an­oth­er use on its Keytru­da la­bel — this time, as the first ad­ju­vant im­munother­a­py for cer­tain re­nal cell car­ci­no­ma pa­tients af­ter they’ve had kid­ney surgery.

The FDA has ap­proved Keytru­da in the ad­ju­vant set­ting three weeks be­fore its goal date, mark­ing the lat­est in a streak of la­bel ex­pan­sions and giv­ing the PD-1 su­per­star a leg up on its check­point in­hibitor ri­vals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER